Articles Archives - Page 550 of 795

FridayOct 16, 2020 10:57 am

180 Life Sciences Corp. Expands IP Portfolio with EU, U.S., and Chinese Patents

The company’s patent portfolio includes its own intellectual property and exclusive worldwide licenses, including in the U.S., Canada, Europe, Australia, Hong Kong, and China 180 Life Sciences is in the final stages of its merger process with KBL Merger Corp. IV, with the resulting entity to list on NASDAQ under the ticker “ATNF” The company is devoting its clinical-stage biotechnology research to producing solutions that will help battle inflammation. Its primary focus is to treat fibrosis and inflammation using anti-TNF therapy The estimated annual market size for anti-inflammatory therapeutics is projected to grow to an estimated $106.1 billion in 2020.…

FridayOct 16, 2020 10:19 am

Rritual Mushrooms Inc. Takes Aim at New Wellness Industry in Functional Foods Marketplace

Rritual Mushrooms Inc. is an emerging producer of premium plant-based superfood products designed to help people meet the demands of modern life with style and ease The company introduced the wellness and nutraceuticals market to its suite of three mushroom and adaptogen-based elixir powders in September Rritual Mushrooms’ products were created to boost immunity, support brain function and help the body fight anxiety Rritual is positioned to take advantage of lifestyle trends that have promoted plant-based proteins and reduced meat consumption in recent years, as well as an invigorated interest in immunity-enhancing substances brought on by the worldwide COVID-19 pandemic…

ThursdayOct 15, 2020 1:13 pm

Net Element Inc. (NASDAQ: NETE) Well-Poised to Capitalize as EV Market Set to Grow by 29% per Annum Over Next Decade

Net Element’s reverse merger with EV manufacturer Mullen Technologies expected to close by 4Q2020 Mullen expects to begin marketing Dragonfly K50, sold in conjunction with JV partner Qiantu Motors from 2Q2021 followed by its own EV SUV in 2022 Deloitte expects annual EV sales to rise from 2.5mn in 2020 to 31.1mn in 2030, implying 29% CAGR over next ten years By 2030, EVs expected to account for 32% of all automobile sales globally, approximately 27% in United States Net Element (NASDAQ: NETE), a financial technology company which has recently transformed its business model to become a pure-play electric vehicle…

ThursdayOct 15, 2020 12:23 pm

AzurRx BioPharma Inc. (NASDAQ: AZRX) is “One to Watch”

AzurRx BioPharma’s lead therapeutic, MS1819, is a recombinant lipase treatment for exocrine pancreatic insufficiency and is currently targeting patients with cystic fibrosis and chronic pancreatitis – an established global market of more than $2 billion The company is currently pursuing parallel monotherapy and combination therapy trials, which are anticipated to produce topline data in Q1 2021 and Q2 2021, respectively Previously completed clinical trials of MS1819 showed primary and secondary endpoint efficacy, with a positive safety profile To fully finance its ongoing Phase 2 trials and being preparations for a pivotal Phase 3 study in 2021, as well as to…

WednesdayOct 14, 2020 1:10 pm

Pure Extract Technologies Inc. Leveraging Growing Popularity of Medicinal Mushrooms in Mainstream Medicine

Scientific research suggests some mushrooms can provide mental benefits, anti-tumor effects, improved immune function, anti-viral properties and detoxification “Psychedelic” varieties currently being studied for depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease, addiction Pure Extracts is expanding into functional mushroom market; Company is currently licensed by Health Canada to buy, sell, produce cannabis products Mushrooms have been used for thousands of years in Eastern medicine to combat illness, increase mental cognition and improve digestion. As their popularity continues to increase worldwide, Pure Extract Technologies, a privately held, plant-based, Canadian extraction company is leveraging the growing acceptance by mainstream science and the…

WednesdayOct 14, 2020 12:33 pm

180 Life Sciences Corp. Bringing Hope to Those Afflicted by Dupuytren’s Disease and Other Inflammatory Conditions

180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions. Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with first results expected in 2021 The company is to be acquired by a SPAC (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF Pioneering biotech company, 180 Life Sciences Corp. is bringing hope to sufferers of Dupuytren’s Disease and other inflammatory conditions caused by an impaired immune system. Currently, the company has three major programs…

WednesdayOct 14, 2020 11:20 am

Gage Cannabis Co. is “One to Watch”

Gage Cannabis is one of the leading vertically integrated operators in the cannabis industry Its current focus is the Michigan market, which is valued at an estimated $3 billion and recorded $109 million in cannabis sales in August 2020 The company currently has five dispensaries across Michigan, with the potential to have 90% of the state’s population within a one-hour drive as it continues to expand its dispensary network, offering a wide range of products and even home delivery options Gage is planning to expand its cultivation site in Monitor Township and open an additional 3-4 provisioning centers (dispensaries) in…

TuesdayOct 13, 2020 2:00 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Takes Another Step Closer to Q1 Launch of Brain Cancer Drug Trial

CNS Pharmaceuticals is a pre-clinical-stage developer of novel brain cancer-fighting drugs, including its lead candidate Berubicin The company is working to build on promising results from a 2006 Phase I trial, which provided 44 percent of its limited patient pool with clinically significant improvement in disease stability and one patient with a durable complete response (no evidence of any tumor remaining) for over 14 years CNS Pharmaceuticals expects to launch a pivotal Phase II trial of Berubicin at the beginning of next year and has been assembling a team of partner companies help with the trial CNS recently announced that…

TuesdayOct 13, 2020 1:20 pm

Predictive Oncology Inc. (NASDAQ: POAI) CEO Schwartz Pens Letter to Shareholders, Elaborates on Ongoing Company Developments

Predictive Oncology’s CEO Carl Schwartz published open letter to company’s shareholders Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward CEO also revealed that company’s revenue trends have stabilized and are now on upward trend with cash burn beginning to decline Company also revealed its ability to access over $10 million in undrawn equity lines of credit Carl Schwartz, the CEO of Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has recently published a…

TuesdayOct 13, 2020 12:51 pm

Kaival Brands Innovations Group Inc. (KAVL) Acquires Patent, Announces Lab, Enters Smoking Cessation Market

KAVL recently acquired patent, announced creation of wholly owned subsidiary to develop smoking cessation products. Company plans to create products that satisfy smokers but are free from nicotine’s addictive traits. CEO says company is excited to help “all nicotine users lead healthier and higher-quality lives.” The Centers for Disease Control and Prevention report that smoking is the leading cause of preventable death in the world today (https://ibn.fm/dxZ1W). With the help of new and innovative cessation products, the 7 million deaths that occur every year due to smoking could be prevented — and Kaival Brands Innovations Group (OTCQB: KAVL) is determined to do…

Site Search

Company Search

Category: Articles